TY - JOUR
T1 - A pilot phase II trial of magnesium supplements to reduce menopausal hot flashes in breast cancer patients
AU - Park, Haeseong
AU - Parker, Gwendolyn L.
AU - Boardman, Cecelia H.
AU - Morris, Monica M.
AU - Smith, Thomas J.
N1 - Funding Information:
Conflicts of interest The authors hereby indicate that they do not have a financial relationship with any organization that sponsored the research. Research support for the investigators comes from the Massey Cancer Center NCI Core Grant 5 P30 CA16059 (TJS, GLP, MM, and CHB); salary support for TJS comes from GO8 LM0095259 from the National Library of Medicine and R01CA116227-01 from the National Cancer Institute. The pilot trial research was sponsored by the VCU-Massey Cancer Center, which has no financial interest in the publication or the results. Indeed, the low cost of oral magnesium (US $0.02 per tablet) precludes any commercial interest and was one of the attractive features of the therapy. The authors note that they have full control of all primary data, which is stored in the secure VCU-Massey ONCOR system, and that they agree to allow the journal to review their data if requested. All authors meet standards for authorship and have made important contributions to the study.
PY - 2011/6
Y1 - 2011/6
N2 - Background We tested if magnesium would diminish bothersome hot flashes in breast cancer patients. Methods Breast cancer patients with at least 14 hot flashes a week received magnesium oxide 400 mg for 4 weeks, escalating to 800 mg if needed. Hot flash score (frequency× severity) at baseline was compared to the end of treatment. Results Of 29 who enrolled, 25 women completed treatment. The average age was 53.5 years; six African American, the rest Caucasian; eight were on tamoxifen, nine were on aromatase inhibitors, and 14 were on antidepressants. Seventeen patients escalated the magnesium dose. Hot flash frequency/week was reduced from 52.2 (standard error (SE), 13.7) to 27.7 (SE, 5.7), a 41.4% reduction, p=0.02, two-sided paired t test. Hot flash score was reduced from 109.8 (SE, 40.9) to 47.8 (SE, 13.8), a 50.4% reduction, p=0.04. Of 25 patients, 14 (56%) had a >50% reduction in hot flash score, and 19 (76%) had a >25% reduction. Fatigue, sweating, and distress were all significantly reduced. Side effects were minor: two women stopped the drug including one each with headache and nausea, and two women had grade 1 diarrhea. Compliance was excellent, and many patients continued treatment after the trial. Conclusions Oral magnesium appears to have helped more than half of the patients and was well tolerated. Side effects and cost ($0.02/tablet) were minimal. A randomized placebo-controlled trial is planned.
AB - Background We tested if magnesium would diminish bothersome hot flashes in breast cancer patients. Methods Breast cancer patients with at least 14 hot flashes a week received magnesium oxide 400 mg for 4 weeks, escalating to 800 mg if needed. Hot flash score (frequency× severity) at baseline was compared to the end of treatment. Results Of 29 who enrolled, 25 women completed treatment. The average age was 53.5 years; six African American, the rest Caucasian; eight were on tamoxifen, nine were on aromatase inhibitors, and 14 were on antidepressants. Seventeen patients escalated the magnesium dose. Hot flash frequency/week was reduced from 52.2 (standard error (SE), 13.7) to 27.7 (SE, 5.7), a 41.4% reduction, p=0.02, two-sided paired t test. Hot flash score was reduced from 109.8 (SE, 40.9) to 47.8 (SE, 13.8), a 50.4% reduction, p=0.04. Of 25 patients, 14 (56%) had a >50% reduction in hot flash score, and 19 (76%) had a >25% reduction. Fatigue, sweating, and distress were all significantly reduced. Side effects were minor: two women stopped the drug including one each with headache and nausea, and two women had grade 1 diarrhea. Compliance was excellent, and many patients continued treatment after the trial. Conclusions Oral magnesium appears to have helped more than half of the patients and was well tolerated. Side effects and cost ($0.02/tablet) were minimal. A randomized placebo-controlled trial is planned.
KW - Breast cancer
KW - Drug treatment
KW - Hot flashes
KW - Menopause
KW - Survivorship
UR - http://www.scopus.com/inward/record.url?scp=80051671110&partnerID=8YFLogxK
U2 - 10.1007/s00520-011-1099-7
DO - 10.1007/s00520-011-1099-7
M3 - Article
C2 - 21271347
AN - SCOPUS:80051671110
SN - 0941-4355
VL - 19
SP - 859
EP - 863
JO - Supportive Care in Cancer
JF - Supportive Care in Cancer
IS - 6
ER -